news011
Pending Litigation to Delay Launch of Generic Asacol
Boehringer Ingelheim’s Roxane Laboratories will postpone until at least November planned sales of its generic version of Asacol, an ulcerative colitis drug, to resolve a patent infringement suit over the drug. In a deal reached recently with Procter & Gamble Pharmaceuticals and Medeva Pharma Suisse — the brand manufacturers of Asacol (mesalamine) — Roxane agreed to delay the drug’s launch to extend the trial’s discovery phase in the U.S. District Court for the District of New Jersey.
Generic Line
News & Events
- Food and Drug Administration NOTICES Meetings: Internationa... Read more>>
- FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
- Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
- Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
- T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
- Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
- New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
- in vivo Pharmacodynamic Assay Trevigen offers a validated assay with higher sensitivity and... Read more>>
- FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
- Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
- Key Protein Aids In DNA Repair Scientists have shown in multiple contexts that DNA damage ov... Read more>>
- Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>